NICE Publishes Reimbursement Recommendation for Translarna™
February 22, 2023Business Services
London, UK, 22nd February, 2023 — PTC Therapeutics, Ltd. today announced the National Institute for Health and Care Excellence (NICE) has published …
Indegene launches Metaverse capabilities to help life sciences companies create immersive healthcare experiences
February 22, 2023Business Services
Princeton, United States / Bengaluru, India, February 21, 2023: Indegene, a digital-first, life sciences commercialization company today announced the launch …
Modus Therapeutics announces positive topline data from its Phase 1b LPS provocation study evaluating the potential of sevuparin for treatment of sepsis
February 22, 2023Business Services
STOCKHOLM, SWEDEN – 21 February 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet …
FDA approval granted to BD’s HPV assay for use with ThinPrep Pap Test
February 22, 2023Medical Communications
Becton, Dickinson and Company (BD) has received FDA approval for its new HPV assay which will be used in testing …
Pfizer likely to be first to gain FDA approval for new RSV vaccine
February 22, 2023Research and Development
The FDA is expected to approve Pfizer’s new respiratory syncytial virus (RSV) vaccine this summer following its acceptance of the …
Beckley Psytech receives FDA Investigational New Drug (IND) approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT (Mebufotenin)
February 21, 2023Business Services
Oxford, United Kingdom – 21 FEBRUARY 2023 – Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric …
Unum UK expands employee digital health app
February 21, 2023Medical Communications
Employee benefits provider Unum UK has expanded its available modules on its Help@hand app, which aims to provide digital health …
CSL receives CMA from the European Commission for haemophilia B drug
February 21, 2023Medical Communications
CSL, a biotech company, has announced that it has received conditional marketing authorisation (CMA) from the European Commission (EC) for …
Hemab secures $135m in Series B funding for rare bleeding disorder treatment
February 21, 2023Research and Development
Hemab Therapeutics announced it received $135m from their oversubscribed Series B funding round. The funding will be used for their …
Scancell shares encouraging results from phase 1/2 cancer trial
February 21, 2023Research and Development
Scancell Holdings PLC have shared early results from its phase 1/2 cancer study which appear “very encouraging”, according to one …
AstraZeneca and MSD present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
February 20, 2023Business Services
Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer …
SMC recommends Opdivo® (nivolumab) for use post-surgery in specific urothelial cancer patients
February 20, 2023Business Services
(Uxbridge, Middlesex, 13 February 2023) – The Scottish Medicines Consortium (SMC) has accepted Bristol Myers Squibb’s (BMS’) nivolumab for the …
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
February 20, 2023Business Services
PARIS, FRANCE, STRICTLY EMBARGOED until 11.00pm CET, 13 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, …
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic CastrationResistant Prostate Cance
February 20, 2023Business Services
BEERSE, BELGIUM, 16 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the …
FDA approves Apellis’ geographic atrophy treatment
February 20, 2023Medical Communications
Apellis’ Syfovre (pegcetacoplan injection) is indicated for patients with geographic atrophy (GA) with or without subfoveal involvement, and has received …
Medtronic’s extravascular defibrillator receives CE mark
February 20, 2023Medical Communications
Medtronic has received CE mark for its extravascular defibrillator. The Aurora EV-ICD™ MRI SureScan™ and Epsila EV™ MRI SureScan™ defibrillation …
Pfizer’s Lyme disease vaccine study cut due to protocol violations
February 20, 2023Medical Communications
Valneva and Pfizer have seen their Lyme disease vaccine study cut down after some clinical trial sites were revealed to …
Stryker’s Q Guidance System received FDA clearance for cranial applications
February 20, 2023Sales and Marketing
Stryker, a medical technology company, has announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from …
Sun Pharma recalls at least 34,000 bottles of generic drug
February 13, 2023Medical Communications
Mumbai-based pharma company, Sun Pharma, has announced that it is recalling over 34,000 bottles of a generic drug, Diltiazem Hydrochloride, …
REGENXBIO presents interim phase 2 data from drug developed on NAVXpress™ platform
February 13, 2023Manufacturing and Production
REGENXBIO, a clinical-stage biotech company, has announced positive phase 2 data for their drug RXG-314, which was developed by the …
Latest content
FibroFind appoints Lee Borthwick as CEO
